Klin Farmakol Farm. 2020;34(4):175-178

Ceftazidime/avibactam in the therapy of infectius complications in patient with critical burns and inhalation injury

Martin Hladík^1,2, Břetislav Lipový^1,2, Markéta Hanslianová³, Filip Raška^1,2, Ivan Suchánek^1,2

¹ Klinika popálenin a plastické chirurgie FN Brno

² Lékařská fakulta, Masarykova univerzita Brno

³ Oddělení klinické mikrobiologie FN Brno

Management of infectious complications is one of the key aspects of the therapy of patients with burn injuries. Especially patients with severe and critical burns are everyday confronted with various pathogens. Therapy of severe burn injury is long-term and we can observe the increase of antimicrobial resistance in these pathogens which often leads to complicated antimicrobial strategy with limited therapeutical possibilities. Introduction of new antimicriobial drugs is essential. One of the last respresentatives of new antibiotics is ceftazidime/avibactam. Ceftazidime/avibactam is a new member of cefalosporine family with non-betalactam, betalactamase-inhibitor. General indication criteria for ceftadime/avibactam treatment include complicated intraabdominal infections, complicated urinary infections, nosocomial and ventilator-associated pneumonia and infections caused by gram-negative multiresistant pathogens with limitation of terapeutical possibilities. In this article, we present a case study of patient with critical burns and infectious complications caused by multiresistant strains of enterobacteria.

Keywords: ceftazidime/avibactam, burns, resistance of bacteria, infectious complications.

Published: December 22, 2020  Show citation